GB201518466D0 - Use - Google Patents

Use

Info

Publication number
GB201518466D0
GB201518466D0 GBGB1518466.6A GB201518466A GB201518466D0 GB 201518466 D0 GB201518466 D0 GB 201518466D0 GB 201518466 A GB201518466 A GB 201518466A GB 201518466 D0 GB201518466 D0 GB 201518466D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1518466.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cizzle Biotechnology Ltd
Original Assignee
Cizzle Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cizzle Biotechnology Ltd filed Critical Cizzle Biotechnology Ltd
Priority to GBGB1518466.6A priority Critical patent/GB201518466D0/en
Publication of GB201518466D0 publication Critical patent/GB201518466D0/en
Priority to ES16784956T priority patent/ES2870698T3/en
Priority to PCT/GB2016/053203 priority patent/WO2017068330A1/en
Priority to JP2018538961A priority patent/JP6880046B2/en
Priority to US15/768,946 priority patent/US20180306795A1/en
Priority to CN201680072824.7A priority patent/CN108431032B/en
Priority to EP16784956.1A priority patent/EP3362473B1/en
Priority to AU2016342546A priority patent/AU2016342546B2/en
Priority to CA3002320A priority patent/CA3002320A1/en
Priority to US18/188,958 priority patent/US20230266327A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D8/00—Methods for preparing or baking dough
    • A21D8/02—Methods for preparing dough; Treating dough prior to baking
    • A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01133—Glucan 1,4-alpha-maltohydrolase (3.2.1.133), i.e. maltogenic alpha-amylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1518466.6A 2015-10-19 2015-10-19 Use Ceased GB201518466D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1518466.6A GB201518466D0 (en) 2015-10-19 2015-10-19 Use
CA3002320A CA3002320A1 (en) 2015-10-19 2016-10-14 Use of a fibrinogen capture agent to detect a ciz1 b-variant
US15/768,946 US20180306795A1 (en) 2015-10-19 2016-10-14 Use of a Fibrinogen Capture Agent to Detect a Ciz1 B-Variant
PCT/GB2016/053203 WO2017068330A1 (en) 2015-10-19 2016-10-14 Use of a fibrinogen capture agent to detect a ciz1 b-variant
JP2018538961A JP6880046B2 (en) 2015-10-19 2016-10-14 Use of fibrinogen scavengers to detect Ciz1 b mutants
ES16784956T ES2870698T3 (en) 2015-10-19 2016-10-14 Use of a fibrinogen capture agent to detect a Ciz1 variant b
CN201680072824.7A CN108431032B (en) 2015-10-19 2016-10-14 Application of fibrinogen capture agent in detection of CIZ1B variant
EP16784956.1A EP3362473B1 (en) 2015-10-19 2016-10-14 Use of a fibrinogen capture agent to detect a ciz1 b-variant
AU2016342546A AU2016342546B2 (en) 2015-10-19 2016-10-14 Use of a fibrinogen capture agent to detect a Ciz1 b-variant
US18/188,958 US20230266327A1 (en) 2015-10-19 2023-03-23 Use of a fibrinogen capture agent to detect a ciz1 b-variant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1518466.6A GB201518466D0 (en) 2015-10-19 2015-10-19 Use

Publications (1)

Publication Number Publication Date
GB201518466D0 true GB201518466D0 (en) 2015-12-02

Family

ID=55131247

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1518466.6A Ceased GB201518466D0 (en) 2015-10-19 2015-10-19 Use

Country Status (9)

Country Link
US (2) US20180306795A1 (en)
EP (1) EP3362473B1 (en)
JP (1) JP6880046B2 (en)
CN (1) CN108431032B (en)
AU (1) AU2016342546B2 (en)
CA (1) CA3002320A1 (en)
ES (1) ES2870698T3 (en)
GB (1) GB201518466D0 (en)
WO (1) WO2017068330A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079914A1 (en) * 2017-10-23 2019-05-02 蔡胜和 Anti-ciz1 antibody
CN110448719B (en) * 2019-06-28 2020-05-22 浙江大学 Silk fibroin-polypeptide electrospun membrane for promoting blood coagulation and preparation method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
GB0228337D0 (en) 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein
AU2004227018A1 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
US20140113310A9 (en) * 2008-12-05 2014-04-24 Myriad Genetics, Incorporated Cancer detection markers
GB0901837D0 (en) * 2009-02-05 2009-03-11 Cizzle Biotechnology Ltd Cancer diagnosis and treatment
BRPI0924286A2 (en) * 2009-03-30 2016-01-26 Amdl Inc detection of fibrinogen and fibrin degradation products and associated methods of production and use for cancer detection and monitoring
CA2791905A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
AU2011287430A1 (en) * 2010-08-04 2013-03-21 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of cancer
US20120183489A1 (en) 2011-01-14 2012-07-19 Ricky Ah-Man Woo Compositions comprising metallated malodor control polymers
CN103421886B (en) * 2012-05-21 2018-10-12 上海吉凯基因化学技术有限公司 The purposes and its related drugs of CIZ1 genes
CA2936100A1 (en) * 2013-12-04 2015-06-11 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Also Published As

Publication number Publication date
ES2870698T3 (en) 2021-10-27
CA3002320A1 (en) 2017-04-27
JP2019500618A (en) 2019-01-10
JP6880046B2 (en) 2021-06-02
AU2016342546A1 (en) 2018-06-07
CN108431032A (en) 2018-08-21
CN108431032B (en) 2022-12-20
US20180306795A1 (en) 2018-10-25
AU2016342546B2 (en) 2022-08-18
EP3362473A1 (en) 2018-08-22
EP3362473B1 (en) 2021-04-07
WO2017068330A1 (en) 2017-04-27
US20230266327A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
DK3320033T3 (en) Polyethylenterephthalat-depolymerisering
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
GB201502152D0 (en) Novel use
DK3298030T3 (en) Anti-cancerfusionspolypeptid
DK3250592T3 (en) Anti-transthyretin-antistoffer
GB201509326D0 (en) Novel use
DK3336185T3 (en) Antistof
DK3272750T3 (en) Morphinan-derivat
DK3324768T3 (en) Tørdragt
AU361999S (en) Ballustrade
GB201522311D0 (en) Use
GB201522309D0 (en) Use
GB201521085D0 (en) Use
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB201518466D0 (en) Use
GB201510077D0 (en) Use
GB201516249D0 (en) Liqui-glove
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201518831D0 (en) New use
GB201522411D0 (en) Use
GB201522443D0 (en) Use
AU5516P (en) LEP08 Lepidosperma squamatum
GB201515987D0 (en) Use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)